|
 WASHINGTON (AP) - Diabetics are getting an alternative to the regular needle jabs of insulin they've endured since the discovery in the 1920s of the hormone that controls blood sugar levels.
Pfizer Inc. hopes to begin selling Exubera, the first inhalable version of insulin to win federal approval, by midyear.
Use of rapid-acting inhaled insulin will not replace the need to inject the hormone occasionally, the Food and Drug Administration said. It approved Exubera on Friday, a day after the multinational European Commission did so.
|